「病人反应更大」这句话,先要问是哪把尺子量的:接地-穴位阻抗的病理放大效应与四层假象

Written by

in

Language

Evidence level: B

交互项显著只说明两组的变化量不相等,不说明病理状态放大了效应——在两组基线不同、入组规则不同、测量系统不同的情况下,「放大」可以完全由除法和招募方式造出来。

正文

上一篇确立了一个前提:接地会系统性地扰动穴位阻抗,而这种扰动是否具穴位特异性,要看「接地×测点类别」的交互项。本主题把交互项里的第二个因素从「穴位 vs 旁开点」换成「病人 vs 健康人」:如果慢性疼痛或失眠患者的接地-阻抗响应幅度大于健康对照,是否说明病理状态放大了这个界面效应?

这看似只换了分组变量,其实换了一整套统计风险。因为「穴位 vs 旁开点」是在同一个人身上比,两组基线天然共享;而「病人 vs 健康人」是两个人群比,基线、入组规则、用药、测量条件全都不同。交互项在数学上仍然只是一个乘积项,但它此刻承载的因果含义要脆弱得多。至少四层假象,可各自独立造出同一个「放大」。

第一层:放大需要一个共同的「1」。 假设健康组基线 100 kΩ、患者组 70 kΩ,接地后两组都下降 10 kΩ。绝对变化完全相等,但换成相对变化,患者组是 14.3%、健康组是 10%——凭空多出四成「放大」。所以「放大」在绝对 Ω、相对 %、标准化 d 三种尺度下不是同一句话。只报一种尺度的研究,读者分不清它报的是生理还是除法。

第二层:患者组可能根本没有放大的空间。 穴位阻抗对组织水合高度敏感,电容法与阻抗法测的其实是同一件事的不同侧面(PMID 22092664);慢性疼痛与失眠人群常伴局部水肿、出汗改变、皮温异常——复杂区域疼痛综合征的皮温不对称本身就是诊断特征(PMID 35005383)。这些因素普遍把基线阻抗压低。基线已低,再往下的余地就小,真实机制更可能是「压缩」;而压缩与放大在交互项里长得一样,只是符号相反。

第三层,也是最容易被忽略的:差异性回归到均值。 回归到均值不是误差,是选择的必然结果(PMID 15333621;一般表达式见 PMID 40126924)。当两组入组规则不同——健康组随便招、患者组按症状严重度招——两组的极端程度天然不等,重复测量时向均值回落的幅度也就不等;这种差异性回归足以单独造出一个显著的组间变化差(控制思路见 PMID 37284516)。须说清一点:入组按症状选、非按阻抗选,故回归严格讲作用于症状;但本假说的全部内容恰恰是「症状与阻抗相关」,于是症状的回归会顺着这条相关传导到阻抗上。换言之——这个假说越成立,这个假象就越强。

第四层:患者组不是「健康人加一个病」,而是另一套测量系统。 纤维肌痛患者的自主神经功能本身偏离常态(PMID 27152281;昼夜节律分析见 PMID 9811051),失眠的高唤醒模型意味着交感张力基线持续抬高(PMID 19481481),而精神状态与用药都会实质改变皮肤电活动(PMID 2567035)。于是「病/健康」与基线交感张力、皮温、水合、用药史高度共线。交互项显著,只能说明两组在某个未拆分的复合变量上不同,不能说明是疾病机制。

第五层:即使一切干净,检验本身也不给力。 交互项检验的功效通常只有同等主效应检验的四分之一量级(PMID 15066682);亚组分析的假阳性与假阴性风险早有量化(PMID 11701102),「总体无效而某亚组有效」在统计上完全可能(PMID 23939947)。更麻烦的是把严重度做成「病/不病」的二分——二分连续变量会系统性低估效应并损失功效(PMID 22457338)。十几人对十几人的研究报出「放大四成」,多半是几层假象的合力。

所以真正该做的不是把两类人放一起比谁变得多,而是三件更朴素的事。一是用配对内差值,不用组间事后比:交叉设计里每个人自己的「接地减非接地」差值已经带走了他自己的基线,回归到均值在配对差值里被大幅抵消——这是交叉设计最被低估的价值,也最该被本主题利用。二是三种尺度同时报,并事先声明「放大」只在绝对、相对、标准化三向同向时成立;三向不一致时正确的表述是「两组变化在尺度上不可比」,不是「病人更敏感」。三是把严重度当连续变量做调节,用连续×处理的交互项代替两个人群的硬分组,并预注册方向与最小可检交互量;估不出交互量就先做剂量探索,别先做人群对比。

还有一条反向的、不能回避的证据:在安慰剂镇痛这个最经典的「病人是否更敏感」问题上,慢性疼痛患者(骨关节炎与纤维肌痛)与健康人的反应幅度、可重复性并无差异(PMID 32639369)。这不能证明接地也如此,但它把举证责任放回了「放大」这一侧。

易学落点。《素问·标本病传论》讲「知标本者,万举万当;不知标本,是谓妄行」——标本在这里就是「基线从哪来」。中医从不假设病人是健康人的放大版,它假设病人是另一种格局,所以才有同病异治、异病同治。风水里「福地福人居」其实也在说同一件事:同一个位置对不同的人,不是用同一把尺子量出来的。翻成统计语言就是:别拿两个基线不同的人群的原始变化量直接相减,然后把那个差叫作敏感性。

证据与局限

已验证: 接地即时、全身性、可逆地改变体表电位(PMID 22420736),并伴随血液流变学改变(PMID 22757749),效应综述见 PMID 22291721;接地缓解延迟性肌肉酸痛的初步证据(PMID 20192911);对基线未校正的疼痛试验做 ANCOVA 重分析会实质性改变结论与功效(PMID 15322438);回归到均值是选择效应而非误差,且在任意双变量分布下可量化(PMID 15333621;PMID 40126924);差异性回归可独立造成组间变化差,倾向评分可部分校正(PMID 37284516);交互检验功效远低于主效应检验(PMID 15066682);慢性疼痛患者的安慰剂反应幅度与健康人无差异(PMID 32639369)。

部分验证: 纤维肌痛与失眠人群存在自主神经基线偏移(PMID 27152281;PMID 9811051;PMID 19481481),但这是否改变对外部电学干预的响应幅度,尚无直接数据;穴位阻抗与组织水合、皮温的耦合关系明确(PMID 22092664;PMID 35005383),但耦合系数在患病人群中的标定缺失。

待验证: 接地×人群(健康/患病)交互项在三种尺度下是否同向;严重度作为连续调节变量的剂量-反应形状(该课题见后续 #467 方向);配对内差值能否把差异性回归压到可忽略的量级。

相关阅读

证据等级: B
参考文献: PMID 22420736, PMID 22757749, PMID 20192911, PMID 15333621, PMID 40126924, PMID 37284516, PMID 15066682, PMID 11701102, PMID 23939947, PMID 22457338, PMID 22092664, PMID 35005383, PMID 27152281, PMID 9811051, PMID 19481481, PMID 2567035, PMID 32639369, PMID 22291721, PMID 15322438


免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

\”Greater Patient Response\”: Measuring the Pathological Amplification Effect of Ground-Point Acupoint Impedance and the Four-Layer Illusion

Evidence level: B

A significant interaction term only indicates that the magnitude of change differs between two groups; it does not confirm that a pathological state amplifies the effect. Under conditions of differing baselines, varying inclusion criteria, and distinct measurement systems, “amplification” can be entirely generated by division ratios and recruitment methods.

Main Text

The previous article established a premise: grounding systematically perturbs acupoint impedance, and whether this perturbation exhibits acupoint specificity depends on the interaction term of “grounding × measurement site category.” This topic shifts the second factor in that interaction from “acupoint vs. adjacent point” to “patient vs. healthy control”: if the grounding-impedance response magnitude in chronic pain or insomnia patients exceeds that of healthy controls, does this indicate that the pathological state amplifies this interface effect?

This appears to be merely a change in grouping variables, yet it introduces an entirely different statistical risk profile. Comparing “acupoints vs. adjacent points” involves individuals within the same person, sharing natural baselines; conversely, comparing “patients vs. healthy controls” involves distinct populations with differing baselines, inclusion criteria, medication histories, and measurement conditions. Mathematically, the interaction term remains merely a product term, yet its causal interpretation is now far more fragile. At least four illusions can each independently generate the same appearance of “amplification.”

First Illusion: Amplification Requires a Common “1”. Assume the healthy group baseline is 100 kΩ and the patient group is 70 kΩ; after grounding, both groups decrease by 10 kΩ. The absolute change is identical, but when converted to relative change, the patient group shows a 14.3% reduction versus 10% for the healthy group—凭空 creating an extra 40% “amplification.” Thus, “amplification” is not a single statement across absolute Ω, relative %, and standardized d scales. Studies reporting only one scale leave readers unable to distinguish whether they are observing a physiological effect or a mathematical artifact of division.

Second Illusion: The Patient Group May Have No Room for Amplification. Acupoint impedance is highly sensitive to tissue hydration levels; capacitive and impedance methods measure different facets of the same phenomenon (PMID 22092664). Chronic pain and insomnia populations frequently exhibit localized edema, altered sweating, and abnormal skin temperature—skin temperature asymmetry itself is a diagnostic feature for complex regional pain syndrome (PMID 35005383). These factors universally depress the baseline impedance. With a low baseline already established, the room for further reduction is small; the true mechanism is more likely “compression.” Compression and amplification appear identical in interaction terms, differing only in sign.

Third Illusion (Most Easily Overlooked): Regression to the Mean. Regression to the mean is not error but an inevitable result of selection (PMID 15333621; general expression see PMID 40126924). When inclusion criteria differ between groups—random recruitment for healthy controls versus symptom severity-based recruitment for patients—the extremity of the two groups naturally differs. Consequently, the magnitude of return toward the mean during repeated measurements also differs; such differential regression alone can generate a significant between-group difference in change (control logic see PMID 37284516). One clarification is necessary: since selection is based on symptoms rather than impedance, regression strictly acts upon symptoms. However, the entirety of this hypothesis posits a correlation between “symptoms and impedance”; thus, symptom regression transmits along this correlation to impedance. In other words—the more valid this hypothesis is, the stronger this illusion becomes.

Fourth Illusion: The Patient Group Is Not “Healthy Plus a Disease,” But a Different Measurement System. Autonomic function in fibromyalgia patients inherently deviates from norms (PMID 27152281; circadian rhythm analysis see PMID 9811051); the high-arousal model for insomnia implies a persistently elevated baseline sympathetic tone (PMID 194811481); and mental state alongside medication substantially alter skin conductance (PMID 2567035). Therefore, “patient/healthy” status is highly collinear with baseline sympathetic tone, skin temperature, hydration, and medication history. A significant interaction term merely indicates that the two groups differ on some undecomposed composite variable; it cannot confirm a disease mechanism.

Fifth Illusion: Even If Everything Is Clean, the Test Itself Is Weak. The power of interaction tests is typically only one-quarter the magnitude of equivalent main effect tests (PMID 15066682); false positive and false negative risks in subgroup analysis have long been quantified (PMID 11701102), and “overall null with a specific subgroup effect” is statistically entirely possible (PMID 23939947). More problematic is converting severity into a binary “patient/non-patient” classification—binarizing continuous variables systematically underestimates effects and reduces power (PMID 22457338). Studies reporting “40% amplification” from dozens of patients versus dozens of controls are likely the合力 (synergy) of several layers of illusions.

Therefore, the true task is not to compare two groups to see who changed more, but to pursue three simpler actions. First, use within-pair differences rather than between-group post-hoc comparisons: in crossover designs, each individual’s “grounding minus non-grounding” difference already removes their own baseline; regression to the mean is largely canceled out within paired differences—this is the most undervalued value of crossover design, and precisely what this topic should leverage. Second, report all three scales simultaneously, explicitly stating that “amplification” only holds when absolute, relative, and standardized changes align directionally; when they do not, the correct phrasing is “changes between groups are incomparable across scales,” not “patients are more sensitive.” Third, treat severity as a continuous moderator, using a continuous × treatment interaction term instead of hard grouping into two populations, and preregister the expected direction and minimum detectable interaction effect; if an interaction effect cannot be estimated, conduct dose exploration first rather than population comparison.

There is also a reverse piece of evidence that cannot be avoided: in placebo analgesia, the most classic question of “whether patients are more sensitive,” chronic pain patients (osteoarthritis and fibromyalgia) show no difference in response magnitude or reproducibility compared to healthy controls (PMID 32639369). This does not prove the same holds for grounding, but it returns the burden of proof to the side of “amplification.”

Yijing Studies Implication. The Su Wen · Ben Bian Lun states, “He who knows the root and branch acts correctly in all endeavors; he who does not is acting blindly.” Here, “root and branch” refers to “where the baseline originates.” Traditional Chinese medicine never assumes patients are an amplified version of healthy people; it assumes they represent a different pattern, hence the principles of treating the same disease differently or different diseases similarly. In Feng Shui, “a blessed land and a blessed resident” say the same thing: the same location is not measured with the same ruler for different people. Translated into statistical language: do not simply subtract raw change amounts from two populations with different baselines and label that difference as “sensitivity.”

Evidence and Limitations

Verified: Grounding immediately, systemically, and reversibly alters surface potential (PMID 22420736) and is accompanied by hemorheological changes (PMID 22757749); systematic review see PMID 22291721; preliminary evidence for grounding alleviating delayed-onset muscle soreness (PMID 20192911); reanalysis of pain trials without baseline correction via ANCOVA substantially alters conclusions and power (PMID 15322438); regression to the mean is a selection effect not error and is quantifiable under any bivariate distribution (PMID 15333621; PMID 40126924); differential regression can independently generate between-group change differences, propensity scores can partially correct (PMID 37284516); interaction test power is far lower than main effect tests (PMID 15066682); placebo response magnitude in chronic pain patients shows no difference from healthy controls (PMID 32639369).

Partially Verified: Baseline autonomic shifts exist in fibromyalgia and insomnia populations (PMID 27152281; PMID 9811051; PMID 19481481), but whether this alters response magnitude to external electrical interventions lacks direct data; coupling between acupoint impedance and tissue hydration/skin temperature is clear (PMID 22092664; PMID 35005383), but calibration of coupling coefficients in diseased populations is missing.

To Be Verified: Whether the grounding × population (healthy/diseased) interaction is consistent across all three scales; dose-response shape of severity as a continuous moderator (see subsequent #467 direction); whether within-pair differences can suppress differential regression to negligible levels.

Related Reading

Evidence Level: B
References: PMID 22420736, PMID 22757749, PMID 20192911, PMID 15333621, PMID 40126924, PMID 37284516, PMID 15066682, PMID 11701102, PMID 23939947, PMID 22457338, PMID 22092664, PMID 35005383, PMID 27152281, PMID 9811051, PMID 19481481, PMID 2567035, PMID 32639369, PMID 22291721, PMID 15322438


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *